Director, Immune Safety Immunology – Hybrid

Biopharma Careers; Ridgefield (CT); Hybrid; USD 200,000 - 316,000; Full time

Job summary

Boehringer Ingelheim in Ridgefield, CT seeks a Director Early Safety Immunology to lead the immunology safety program across discovery, preclinical and clinical development. The role requires guiding a team of scientists, setting strategy, and delivering mechanistic data to portfolio decisions.

The position is site-based with flexibility for remote work; onsite 2-3 days weekly, with cross-functional collaboration and global exposure to drive immune safety and novel biomarker development.

Qualifications

• Ph.D. in Immunology with roughly ten years in pharma.
• Extensive experience in immune safety assessments and mechanistic derisking studies.
• Strong leadership and staff development experience, incl. senior scientists.
• Ability to lead in dynamic, evolving environments and guide teams through ambiguity.

Responsibilities

• Manages a group of 15–25 FTEs conducting immune safety studies across discovery, preclinical and clinical development.
• Provides scientific oversight, strategy, and context for Early Safety Immunology projects.
• Maintains operational control, balancing assignments, workload, and resources.
• Interprets computational, molecular, and immunotoxicology data to support mechanism understanding.
• Ensures compliance with regulatory standards and maintains cross-functional collaboration.

Skills

Immunology

Leadership

Strategic planning

Communication

Education

PhD in Immunology

Job description

Boehringer Ingelheim in Ridgefield, CT seeks a Director Early Safety Immunology to lead the immunology safety program across discovery, preclinical and clinical development. The role requires guiding a team of scientists, setting strategy, and delivering mechanistic data to portfolio decisions.

The position is site-based with flexibility for remote work; onsite 2-3 days weekly, with cross-functional collaboration and global exposure to drive immune safety and novel biomarker development.